Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
6.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors at 6 institutions in 1 country.
Cindy ImDepartment of Pediatrics, University of Minnesota, Minneapolis, MN.ORCID 0000-0003-0931-9432
Achal NeupaneDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.
Jessica L BaedkeDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-5085-4985
Brian LennyDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.
Angela DelaneyDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0002-0632-6365
Stephanie B DixonDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0003-3901-3274
Eric J ChowPublic Health Sciences and Clinical Research Divisions, Fred Hutchinson Research Center, Seattle, WA.ORCID 0000-0001-7712-961X
Sogol Mostoufi-MoabDepartment of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.ORCID 0000-0002-8623-1138
Tianzhong YangDepartment of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN.ORCID 0000-0002-0162-7740
Melissa A RichardSection of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.ORCID 0000-0003-0129-9860
M Monica GramatgesSection of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.ORCID 0000-0002-0947-104X
Philip J LupoSection of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.ORCID 0000-0003-0978-5863
Noha SharafeldinInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0001-8835-8899
Smita BhatiaInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0002-7755-5683
Gregory T ArmstrongDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.
Melissa M HudsonDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-6984-2407
Kirsten K NessDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0002-2084-1507
Leslie L RobisonDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-7460-8578
Yutaka YasuiDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0002-7717-8638
Carmen L WilsonDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-7636-065X
Yadav SapkotaDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-5943-9454
St. Jude Children's Research Hospital · USBaylor College of Medicine · USUniversity of Alabama at Birmingham · USUniversity of Minnesota · USChildren's Hospital of Philadelphia · USFred Hutch Cancer Center · US
Funding
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
Mach-LETSGO: Machine-LEarning of Treatment, Survey, and Genetics towards Obtaining Correct Classification of Chronic Conditions in Adult Survivors in the Childhood Cancer Survivor Study - CCSS SupplU24CA055727 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Gregory Armstrong · 1999 to 2026
$96.7M
The St. Jude Lifetime CohortU01CA195547 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HUDSON, MELISSA M, NESS, KIRSTEN KIMBERLIE · 2015 to 2024
$14.9M
Predicting and Preventing Chemotherapy-InducedCardiotoxicity in African American ChildrenR01CA261898 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BURRIDGE, PAUL W., SAPKOTA, YADAV · 2021 to 2025
$3.6M
Late Effects Prediction using Clinical Phenotypes and Whole Genome SequencingR01CA216354 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI YASUI, YUTAKA, ZHANG, JINGHUI · 2017 to 2021
$3.4M
Developing and validating race-specific cardiomyopathy risk prediction models in African American survivors of childhood cancerR01HL173881 · NHLBI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Cindy Im, Yadav Sapkota · 2024 to 2026
$2.3M
Treatment-specific genetic risk scores for late effects prediction in childhood,adolescent, and young adult cancer survivorsR21CA261833 · NCI · UNIVERSITY OF MINNESOTA · PI IM, CINDY, YUAN, YAN · 2021 to 2021
purposeType 2 diabetes mellitus (T2D) is a prevalent long-term complication of treatment in survivors of childhood cancer, with marked racial/ethnic differences in burden. In this study, we investigated trans-ancestral genetic risks for treatment-related T2D. PATIENTS AND
methodsLeveraging whole-genome sequencing data from the St Jude Lifetime Cohort (N = 3,676, 304 clinically ascertained cases), we conducted ancestry-specific genome-wide association studies among survivors of African and European genetic ancestry (AFR and EUR, respectively) followed by trans-ancestry meta-analysis. Trans-/within-ancestry replication including data from the Childhood Cancer Survivor Study (N = 5,965) was required for prioritization. Three external general population T2D polygenic risk scores (PRSs) were assessed, including multiancestry PRSs. Treatment risk effect modification was evaluated for prioritized loci.
resultsFour novel T2D risk loci showing trans-/within-ancestry replication evidence were identified, with three loci achieving genome-wide significance (
conclusionOur findings suggest therapy-related genetic risks contribute to the increased T2D burden among non-Hispanic Black childhood cancer survivors. Additional study of how therapy-related genetic susceptibility contributes to this disparity is needed.
Indexed as
Cancer SurvivorsDiabetes Mellitus, Type 2Genome-Wide Association StudyNeoplasmsAdolescentAdultBlack PeopleChildFemaleGenetic Predisposition to DiseaseHumansMaleRisk FactorsWhite People
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Trans-Ancestral Genetic Risk Factors for Treatment-Related Type 2 Diabetes Mellitus in Survivors of Childhood Cancer. · full record | OpenQuestion